A Phase I Dose Escalation Study of SGN-35 Alone and in Combination With Gemcitabine for CD30-Positive Malignancies

Stopped Sponsor decision not to enroll cohorts of combined SGN-35 and gemcitabine therapy.

Conditions

• Disease, Hodgkin
• Lymphoma, Large-Cell, Anaplastic
• Lymphoma, Non-Hodgkin

Interventions

• DRUG: SGN-35
• DRUG: gemcitabine

Sponsor

Seagen Inc.